Privately-held Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial ...

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an ...

Galderma floated on the SIX Swiss Exchange in Zurich on March 22, ending the first trading day up 20.75 percent. Nicolas ...

Several shareholders of the Swiss pharmaceutical company Galderma Group AG plan to sell 6.7% of the shares for 1.28 billion Swiss francs ($1.45 billion). This is reported by foreign media. EQT AB, the ...

The P 91 intermittent motion cartoner from Promatic has been in use at Galderma for over a year. In the French factory at Alby-sur-Chéran, the Swiss manufacturer of dermatological products declared ...

Nemluvio's approval came in shortly after Galderma announced an R&D alliance with cosmetics giant L'Oreal, which has taken a 10% stake in the Swiss company. Galderma was originally formed as a ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

according to dermatology group Galderma. The Swiss company, which was spun out from Nestlé in 2019 and went public last year, has seen its share price soar as the popularity of products ...

L’Oréal just announced it acquired a 10% stake in Galderma, characterized as a “pure play dermatology leader” in injectibles with Botox-competitor Dysport, and Restylane filler brands.

Swedish private equity firm EQT AB is looking to take advantage of an improving stock market to monetize more exits via ...

Flemming Ornskov, the chief executive of the Swiss dermatology company Galderma, said weight-loss drugs caused “facial sagging”, which some people felt needed rectifying with cosmetic work.